Abstract
A 4-week, double-blind, placebo-controlled trial of amantadine was conducted in 61 cocaine dependent outpatients. Subjects received 100 mg of amantadine 3 times daily. A follow-up visit was conducted at week 8. There were no significant differences between groups in treatment retention, or in the number of benzoylecgonine positive urine samples. Self-reported drug and alcohol use declined in both groups. At week 8 follow-up, self-reported drug use was significantly lower in the placebo group. Amantadine was not effective, and discontinuation of it may have been associated with an increase in cocaine use.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Alcoholism / diagnosis
-
Alcoholism / psychology
-
Alcoholism / rehabilitation
-
Amantadine / therapeutic use*
-
Cocaine*
-
Comorbidity
-
Dopamine Agents / therapeutic use*
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Administration Schedule
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Opioid-Related Disorders / diagnosis
-
Opioid-Related Disorders / psychology
-
Opioid-Related Disorders / rehabilitation*
-
Substance Abuse Detection
-
Treatment Outcome
Substances
-
Dopamine Agents
-
Amantadine
-
Cocaine